CAT Gains from AZ Antibody Drive
Executive Summary
AstraZeneca PLC's November 22 drug development alliance with Cambridge Antibody Technology Group PLC was the Big Pharma's second major commitment to large molecules within little more than a year. AZ's desire to embrace biologicals-- evident since its October 2003 cancer deal with Abgenix Inc. --reflects a growing movement among many hitherto small molecule-focused pharma firms to bolster their anemic pipelines with specialty products. And given its lack of experience in protein development, AZ was prepared to accept a deal structure that was unusually favorable to the biotech. Both this and the deal's timing are good news for CAT.
You may also be interested in...
Amgen/Abgenix: All About a Drug
Amgen is using its cash to buy near-term products-the fundamental reason behind its purchase of Abgenix. Indeed, the irony to this transaction is that while the promise of genomics generated the money Abgenix needed to stay alive, the product that ultimately made Abgenix's fortune is an antibody to an entirely pre-genomic target, the fourth in its target class to make it to market, and the second antibody to do so.
AstraZeneca R&D: Balancing Caution & Ambition
Late-stage setbacks recently forced AstraZeneca to re-think its risk management in the development and regulatory stages, but the process has already started within discovery research. Head of discovery Jan Lundberg told the audience of Windhover's 13th audio-conference in December 2004 how the Big Pharma is adapting to a tougher market environment and attempting to balance caution with ambition.
AstraZeneca R&D: Balancing Caution & Ambition
Late-stage setbacks recently forced AstraZeneca to re-think its risk management in the development and regulatory stages, but the process has already started within discovery research. Head of discovery Jan Lundberg told the audience of Windhover's 13th audio-conference in December 2004 how the Big Pharma is adapting to a tougher market environment and attempting to balance caution with ambition.